Nanoviricides Inc (NNVC)

$1.35 -0.01 (-0.74%)
Market Cap 31.26M
Revenue (ttm) 0.00
Net Income (ttm) -9.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 265,700
Avg Vol 357,532
Day's Range N/A - N/A
Shares Out 22.98M
Stochastic %K 20%
Beta 1.67
Analysts Strong Sell
Price Target $6.33

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
drkazmd65
drkazmd65 Aug. 18 at 12:52 PM
$NNVC - 18-Aug-2026 - The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon Shelton, Connecticut - Tuesday, August 18, 2026. NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo (“DRC”). Professor Patrick Katoto has been appointed as the principal investigator to lead this clinical trial. Dr. Katoto 1 is Co-Director and Co-Founder of the Centre for Tropical Diseases and Global Health (“CTDGH”), and Associate Professor of Medicine, Epidemiology and Global Health at the Catholic University of Bukavu, Bukavu, DRC. He has more than ten years of working experience as a clinician, academic
1 · Reply
Mobler12
Mobler12 Aug. 17 at 10:11 PM
$NNVC The company has posted a PR on their website, dated today (8/17/26) as an informative status update to their Phase II trial for ebola tratement with NV-387 gummies. The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon https://www.nanoviricides.com/
1 · Reply
Mobler12
Mobler12 Aug. 17 at 7:43 PM
$NNVC Hopefully the company will be able to disclose when the Phase II trials, for Ebola treatment, have begun, with the first patients taking NV-387 gummies. That is a really big milestone all by itself.
0 · Reply
STRAYNUT
STRAYNUT Aug. 17 at 6:50 PM
$NNVC Ebola outbreak in Congo becomes deadliest in country's history https://www.msn.com/en-us/health/medical/ebola-outbreak-in-congo-becomes-deadliest-in-countrys-history/ar-AA2aitv6?ocid=BingNewsSerp
0 · Reply
LeftyT
LeftyT Aug. 15 at 3:59 AM
$NNVC Sadly, there will be no shortage of ebola patients to run a quick clinical trial in the Congo. JAMA reports, "As of August 4, the WHO reported 3973 confirmed cases of Bundibugyo virus disease and 1801 deaths, making this the largest Ebola outbreak ever reported in the DRC. The outbreak has reached 5 of 26 provinces in the country, affecting 51 health zones." The rubber will indeed hit the road soon to paraphrase Staynut. I intend to hold on to my shares and find out. https://jamanetwork.com/journals/jama/fullarticle/2853044?guestAccessKey=10ee7840-13bb-4a3a-8066-8a0bebc1654b&utm_medium=email&utm_source=postup_jn&utm_campaign=article_alert-jama&utm_content=olf-tfl_&utm_term=081426#google_vignette
0 · Reply
STRAYNUT
STRAYNUT Aug. 14 at 8:20 PM
$NNVC : Jimmy, if this is such a scam, why would the Congo (DAR) allow the Ebola trial to begin? For a scam to have lasted 21 years as a public company is quite remarkable, don't you think. Just maybe, in that pea brain of yours, your entire premise, that this is a scam, is mistaken. I would love to be a fly on your wall when it finally dawns on you that this technology is second-to-none!
0 · Reply
STRAYNUT
STRAYNUT Aug. 14 at 8:17 PM
$NNVC Playing devil's advocate, you might ask me if this stock is set to explode in price, why the moot reaction to the announcement of FINALLY starting dosing the first Ebola-stricken patient? I have no good answer other than the "rubber now hits the road" and the technology must finally perform as well as the myriad of animal studies have predicted, and some "nervous nellies" have cut and run. A more interesting question is if this technology is so "world class", why hasn't a BPh gobbled it up. The answer is that Dr. Diwan (Anil) has carefully created a Preferred A stock, which among other goodies has 9 votes per share. He owns the bulk of that Preferred, which gives him absolute voting control of the company until he receives an offer that he can't refuse. ALL TO THE GOOD !!!
0 · Reply
Jimmymc1337
Jimmymc1337 Aug. 14 at 3:37 PM
$NNVC re:STRAYNUT comment- read this article before you consider buying this stock even 4 years ago people were noticing this scam stock i don't know how they are still operating https://buyersstrike.com/2022/08/04/monkeypox-update-everything-old-is-new-again-the-continuing-saga-of-bioscam-nanoviricides-nnvc/
0 · Reply
Love1010
Love1010 Aug. 14 at 12:33 PM
$NNVC I've come to the conclusion that STRAYNUT is really NUTS!
0 · Reply
STRAYNUT
STRAYNUT Aug. 13 at 10:27 PM
$NNVC: re: Jimmymc1337 recent comment: NV-387, the Nano therapeutic being used in the Congo Ebola Phase II trial, not only will work, but I suspect all the patients will be cured within 12 days from the start of administration, although the trial is slated to last 30 days, if more is needed. Dosing is one Gummy each morning placed carefully on the tongue and simply allowed to dissolve, which will release BILLIONS of nanoviricides to circulate in the bloodstream and being the same size as the virus particle, will fake out that particle into thinking it is entering a human cell, encapsulate it, and kill it. Dr Diwan has spent 34 years on this invention, which will earn him the Nobel Prize for Medicine, and when trial results are PRed, will send NNVC into the stratosphere.
1 · Reply
Latest News on NNVC
NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’

2026-08-18T12:40:10.000Z - 1 day ago

NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Aug 18, 2026, 8:30 AM EDT - 1 day ago

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

NanoViricides receives regulatory approval for Phase II trial of NV-387

2026-08-10T12:35:59.000Z - 9 days ago

NanoViricides receives regulatory approval for Phase II trial of NV-387

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Aug 10, 2026, 8:30 AM EDT - 9 days ago

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

NanoViricides awaits regulatory approval to being Phase II trial of NV-387

2026-07-28T12:40:29.000Z - 22 days ago

NanoViricides awaits regulatory approval to being Phase II trial of NV-387

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Jul 28, 2026, 8:30 AM EDT - 22 days ago

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

NanoViricides prices $3.8M registered direct offering

2026-07-24T12:10:37.000Z - 26 days ago

NanoViricides prices $3.8M registered direct offering

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

Jul 24, 2026, 8:00 AM EDT - 26 days ago

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial

2026-07-22T12:56:07.000Z - 4 weeks ago

NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial

NanoViricides gets National Ethics Committee approval for Phase II NV-387 trial

2026-07-13T13:30:07.000Z - 5 weeks ago

NanoViricides gets National Ethics Committee approval for Phase II NV-387 trial

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Jul 13, 2026, 9:27 AM EDT - 5 weeks ago

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

Jul 8, 2026, 8:30 AM EDT - 6 weeks ago

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

NanoViricides initiated with an Outperform at Noble Capital

2026-07-06T13:30:07.000Z - 6 weeks ago

NanoViricides initiated with an Outperform at Noble Capital

NanoViricides advances towards Phase II clinical trial of NV-387

2026-07-06T12:45:15.000Z - 6 weeks ago

NanoViricides advances towards Phase II clinical trial of NV-387

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

Jul 6, 2026, 8:30 AM EDT - 6 weeks ago

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

NanoViricides granted Rare Pediatric Disease Drug designation for NV-387

2026-06-29T12:41:04.000Z - 7 weeks ago

NanoViricides granted Rare Pediatric Disease Drug designation for NV-387

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

Jun 29, 2026, 8:30 AM EDT - 7 weeks ago

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo

2026-06-22T13:35:44.000Z - 2 months ago

NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

Jun 22, 2026, 9:30 AM EDT - 2 months ago

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

NanoViricides files to sell 1.33M shares of common stock for holders

2026-06-15T20:41:08.000Z - 2 months ago

NanoViricides files to sell 1.33M shares of common stock for holders

NanoViricides announces proposal approved by Pillar Committee in DRC

2026-06-15T12:41:50.000Z - 2 months ago

NanoViricides announces proposal approved by Pillar Committee in DRC

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

Jun 15, 2026, 8:30 AM EDT - 2 months ago

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

NanoViricides proposes Phase II trial of NV-387 gummies in Ebola

2026-06-08T12:48:36.000Z - 2 months ago

NanoViricides proposes Phase II trial of NV-387 gummies in Ebola

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

Jun 8, 2026, 8:30 AM EDT - 2 months ago

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

NanoViricides files $50M mixed securities shelf

2026-06-05T20:35:24.000Z - 2 months ago

NanoViricides files $50M mixed securities shelf

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

May 26, 2026, 8:30 AM EDT - 3 months ago

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

May 18, 2026, 11:55 PM EDT - 3 months ago

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

NanoViricides emphasizes need for Ebolavirus antiviral drug

2026-05-18T12:35:07.000Z - 3 months ago

NanoViricides emphasizes need for Ebolavirus antiviral drug

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

May 18, 2026, 8:30 AM EDT - 3 months ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

NanoViricides prices $2M registered direct offering

2026-05-15T15:36:54.000Z - 3 months ago

NanoViricides prices $2M registered direct offering

NanoViricides reports Q1 EPS (9c) vs. (14c) last year

2026-05-15T13:02:44.000Z - 3 months ago

NanoViricides reports Q1 EPS (9c) vs. (14c) last year

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

May 15, 2026, 8:35 AM EDT - 3 months ago

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

May 15, 2026, 8:00 AM EDT - 3 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

NanoViricides says hantavirus incident highlights need for antiviral drugs

2026-05-11T15:05:03.000Z - 3 months ago

NanoViricides says hantavirus incident highlights need for antiviral drugs

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

May 11, 2026, 8:30 AM EDT - 3 months ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

May 6, 2026, 3:37 PM EDT - 3 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

May 4, 2026, 8:30 AM EDT - 3 months ago

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Apr 21, 2026, 8:30 AM EDT - 4 months ago

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Apr 7, 2026, 8:30 AM EDT - 4 months ago

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

Apr 1, 2026, 8:30 AM EDT - 5 months ago

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

Mar 11, 2026, 8:30 AM EDT - 5 months ago

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 12, 2026, 8:30 AM EST - 6 months ago

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 10, 2026, 8:30 AM EST - 6 months ago

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

Feb 2, 2026, 8:30 AM EST - 7 months ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

Jan 13, 2026, 8:30 AM EST - 7 months ago

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

Dec 1, 2025, 8:30 AM EST - 9 months ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

Nov 17, 2025, 8:30 AM EST - 9 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

Nov 14, 2025, 8:30 AM EST - 9 months ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 12, 2025, 5:01 PM EST - 9 months ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 11, 2025, 8:30 AM EST - 10 months ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Nov 10, 2025, 8:30 AM EST - 10 months ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Nov 5, 2025, 8:30 AM EST - 10 months ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Nov 3, 2025, 8:30 AM EST - 10 months ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Oct 29, 2025, 8:45 AM EDT - 10 months ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Oct 27, 2025, 8:45 AM EDT - 10 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 22, 2025, 8:45 AM EDT - 10 months ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 20, 2025, 8:45 AM EDT - 10 months ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Oct 15, 2025, 8:45 AM EDT - 11 months ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

NanoViricides, Inc. Has Filed its Annual Report

Sep 30, 2025, 8:45 AM EDT - 11 months ago

NanoViricides, Inc. Has Filed its Annual Report

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 11, 2025, 8:30 AM EDT - 1 year ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 1 year ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Aug 18, 2025, 8:30 AM EDT - 1 year ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 30, 2025, 8:30 AM EDT - 1 year ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 23, 2025, 8:30 AM EDT - 1 year ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025, 6:30 AM EDT - 1 year ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 1 year ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 18, 2025, 6:30 AM EDT - 1 year ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025, 6:55 AM EDT - 1 year ago

NanoViricides Measles Drug Development Animal Study is Imminent

drkazmd65
drkazmd65 Aug. 18 at 12:52 PM
$NNVC - 18-Aug-2026 - The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon Shelton, Connecticut - Tuesday, August 18, 2026. NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo (“DRC”). Professor Patrick Katoto has been appointed as the principal investigator to lead this clinical trial. Dr. Katoto 1 is Co-Director and Co-Founder of the Centre for Tropical Diseases and Global Health (“CTDGH”), and Associate Professor of Medicine, Epidemiology and Global Health at the Catholic University of Bukavu, Bukavu, DRC. He has more than ten years of working experience as a clinician, academic
1 · Reply
Mobler12
Mobler12 Aug. 17 at 10:11 PM
$NNVC The company has posted a PR on their website, dated today (8/17/26) as an informative status update to their Phase II trial for ebola tratement with NV-387 gummies. The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon https://www.nanoviricides.com/
1 · Reply
Mobler12
Mobler12 Aug. 17 at 7:43 PM
$NNVC Hopefully the company will be able to disclose when the Phase II trials, for Ebola treatment, have begun, with the first patients taking NV-387 gummies. That is a really big milestone all by itself.
0 · Reply
STRAYNUT
STRAYNUT Aug. 17 at 6:50 PM
$NNVC Ebola outbreak in Congo becomes deadliest in country's history https://www.msn.com/en-us/health/medical/ebola-outbreak-in-congo-becomes-deadliest-in-countrys-history/ar-AA2aitv6?ocid=BingNewsSerp
0 · Reply
LeftyT
LeftyT Aug. 15 at 3:59 AM
$NNVC Sadly, there will be no shortage of ebola patients to run a quick clinical trial in the Congo. JAMA reports, "As of August 4, the WHO reported 3973 confirmed cases of Bundibugyo virus disease and 1801 deaths, making this the largest Ebola outbreak ever reported in the DRC. The outbreak has reached 5 of 26 provinces in the country, affecting 51 health zones." The rubber will indeed hit the road soon to paraphrase Staynut. I intend to hold on to my shares and find out. https://jamanetwork.com/journals/jama/fullarticle/2853044?guestAccessKey=10ee7840-13bb-4a3a-8066-8a0bebc1654b&utm_medium=email&utm_source=postup_jn&utm_campaign=article_alert-jama&utm_content=olf-tfl_&utm_term=081426#google_vignette
0 · Reply
STRAYNUT
STRAYNUT Aug. 14 at 8:20 PM
$NNVC : Jimmy, if this is such a scam, why would the Congo (DAR) allow the Ebola trial to begin? For a scam to have lasted 21 years as a public company is quite remarkable, don't you think. Just maybe, in that pea brain of yours, your entire premise, that this is a scam, is mistaken. I would love to be a fly on your wall when it finally dawns on you that this technology is second-to-none!
0 · Reply
STRAYNUT
STRAYNUT Aug. 14 at 8:17 PM
$NNVC Playing devil's advocate, you might ask me if this stock is set to explode in price, why the moot reaction to the announcement of FINALLY starting dosing the first Ebola-stricken patient? I have no good answer other than the "rubber now hits the road" and the technology must finally perform as well as the myriad of animal studies have predicted, and some "nervous nellies" have cut and run. A more interesting question is if this technology is so "world class", why hasn't a BPh gobbled it up. The answer is that Dr. Diwan (Anil) has carefully created a Preferred A stock, which among other goodies has 9 votes per share. He owns the bulk of that Preferred, which gives him absolute voting control of the company until he receives an offer that he can't refuse. ALL TO THE GOOD !!!
0 · Reply
Jimmymc1337
Jimmymc1337 Aug. 14 at 3:37 PM
$NNVC re:STRAYNUT comment- read this article before you consider buying this stock even 4 years ago people were noticing this scam stock i don't know how they are still operating https://buyersstrike.com/2022/08/04/monkeypox-update-everything-old-is-new-again-the-continuing-saga-of-bioscam-nanoviricides-nnvc/
0 · Reply
Love1010
Love1010 Aug. 14 at 12:33 PM
$NNVC I've come to the conclusion that STRAYNUT is really NUTS!
0 · Reply
STRAYNUT
STRAYNUT Aug. 13 at 10:27 PM
$NNVC: re: Jimmymc1337 recent comment: NV-387, the Nano therapeutic being used in the Congo Ebola Phase II trial, not only will work, but I suspect all the patients will be cured within 12 days from the start of administration, although the trial is slated to last 30 days, if more is needed. Dosing is one Gummy each morning placed carefully on the tongue and simply allowed to dissolve, which will release BILLIONS of nanoviricides to circulate in the bloodstream and being the same size as the virus particle, will fake out that particle into thinking it is entering a human cell, encapsulate it, and kill it. Dr Diwan has spent 34 years on this invention, which will earn him the Nobel Prize for Medicine, and when trial results are PRed, will send NNVC into the stratosphere.
1 · Reply
Jimmymc1337
Jimmymc1337 Aug. 12 at 8:33 PM
$NNVC scamoviricides avoid this junk at all costs, you will never see an actual phase II trial carried out
0 · Reply
STRAYNUT
STRAYNUT Aug. 11 at 11:00 PM
$NNVC Short Interest (07/31/26) Shares Sold Short 596,850 Change from Last -18.51% Percent of Float 2.41% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
Love1010
Love1010 Aug. 11 at 2:29 PM
$NNVC the market does not believe this company can deliver
1 · Reply
Channelchek
Channelchek Aug. 11 at 1:42 PM
Noble Capital Markets Research Report: NanoViricides ($NNVC) – NanoViricides Receives Regulatory Approval To Begin Phase 2 For Ebola In Africa Regulatory Approval Allows the Phase 2 Trial for NV-387 To Begin. NanoViricides has received approval to proceed with its Phase 2 trial of NV-387 for the treatment of Ebola in the Democratic Republic of Congo (DRC). We expect the Ebola trial to be followed by a separate Phase 2 trial in Mpox, also to be conducted in the DRC. This is consistent with our expected time frame for the trials. Read full report here: https://www.channelchek.com/news-channel/nanoviricides-nnvc-nanoviricides-receives-regulatory-approval-to-begin-phase-2-for-ebola-in-africa
0 · Reply
AlertsAndNews
AlertsAndNews Aug. 10 at 12:30 PM
$NNVC taking gummies to a new level. NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
2 · Reply
Love1010
Love1010 Aug. 6 at 4:16 PM
$NNVC There is definitely a reason this stock is going down. Stay away from Diwan scam ventures.
0 · Reply
Love1010
Love1010 Jul. 31 at 10:43 AM
$NNVC don't believe the hype....they won't deliver in the Congo.
1 · Reply
Jimmymc1337
Jimmymc1337 Jul. 31 at 10:17 AM
$NNVC
0 · Reply
STRAYNUT
STRAYNUT Jul. 30 at 8:15 PM
$NNVC Form 8-K https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320226240&type=PDF&symbol=NNVC&cdn=fe801294bc57d78641f9bbde18f02dcd&companyName=NanoViricides+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-07-30
0 · Reply
STRAYNUT
STRAYNUT Jul. 28 at 11:45 PM
$NNVC Fauci’s Diary Reveals Collusion With Obama to Debunk Beagle Torture Program https://www.zerohedge.com/news/2026-07-28/faucis-diary-reveals-collusion-obama-debunk-beagle-torture-program
1 · Reply
STRAYNUT
STRAYNUT Jul. 28 at 1:17 PM
$NNVC NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial https://finance.yahoo.com/healthcare/articles/nanoviricides-awaits-approval-dr-congo-123000434.html
1 · Reply
4by
4by Jul. 27 at 5:04 PM
$NNVC They were established in 2005. What have they been doing for the last 20+ years?
1 · Reply